Kodiak Sciences, a Palo Alto, CA, eye drug developer, has appointed Jason Ehrlich to serve as chief medical officer and chief development officer. Ehrlich comes to Kodiak from Roche subsidiary, Genentech, where he was global head, clinical ophthalmology. Recently, Kodiak filed for an IPO to finance clinical trials testing its lead drug, KSI-301, in patients who have the “wet” form of age-related macular degeneration.
Sponsored · Special Report
Hyperinflation in rents is over
Hughes Marino
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
Sponsored · Whitepaper
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
Brex
